慢阻肺急性加重住院期间右心室舒张末期容积与结局
该研究为前瞻性观察队列,纳入148例住院慢阻肺急性加重患者,用动态回顾性心电门控CT测量右心室舒张末期容积指数(RVEDVI)。结果示高RVEDVI者入院前12个月住院更频繁、呼吸困难更重,随访死亡更高,RVEDVI与死亡独立相关但处临界显著性。
要点
- 住院慢阻肺急性加重患者中高RVEDVI占51%,与更频繁住院和更重呼吸困难相关。
- RVEDVI升高与长期随访死亡增加相关,多变量校正后关联处于临界显著性。
- 将RVEDVI加入BODE、ADO、DOSE死亡预测模型可改善模型拟合。
核心结论
- 住院慢阻肺急性加重患者中,较高的右心室舒张末期容积与更差的急性临床参数及更高的死亡风险相关。
研究设计与样本
- 住院慢阻肺急性加重期间行动态回顾性心电门控CT,RVEDVI按Framingham Offspring Cohort值定义为正常或升高。
- 共纳入148例参与者(70±10岁[mean±SD],88例[59%]为男性),其中75例(51%)RVEDVI升高。
主要发现
- RVEDVI升高者入院前12个月住院更频繁(52/75[69%] vs. 38/73[52%],p=0.04)。
- RVEDVI升高者呼吸困难更重(改良英国医学研究委员会评分2.9±1.3 vs. 2.4±1.2,p=0.007)。
- 随访期间高RVEDVI与更高死亡相关(log-rank p=0.001)。
- 单变量Cox回归:RVEDVI每增加1 ml/m2,死亡风险HR 1.02(95%CI 1.01,1.03;p=0.001)。
- 多变量Cox回归:RVEDVI与死亡独立相关(HR 1.01 per ml/m2;95%CI 1.00,1.03;p=0.050),处临界显著性水平。
关键数值与推荐
- RVEDVI以Framingham Offspring Cohort值界定正常或升高。
- 将RVEDVI加入三种慢阻肺死亡预测系统后模型拟合改善(合并卡方检验:BODE p=0.05,ADO p=0.04,DOSE p=0.02)。
临床怎么用
- 对住院慢阻肺急性加重患者,可关注CT所测RVEDVI以识别死亡风险更高者。
- RVEDVI或可作为慢阻肺死亡预测模型的补充指标,但多变量关联仅为临界显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Right ventricular (RV) volumes are crucial outcome determinants in pulmonary diseases. Little is known about the associations of RV volumes during hospitalized acute exacerbations of chronic obstructive pulmonary disease (AECOPD). We aimed to ascertain associations of RV end-diastolic volume indexed to body surface area (RVEDVI) during hospitalized AECOPD and its relationship with mortality in long-term follow-up. METHODS: This is a prospective observational cohort study (December 2013-November 2019, ACTRN12617001562369) using dynamic retrospective ECG-gated computed tomography during hospitalized AECOPD. RVEDVI was defined as normal or high using Framingham Offspring Cohort values. Cox regression determined the prognostic relevance of RVEDVI for death. RESULTS: A total of 148 participants (70 ± 10 years [mean ± SD], 88 [59%] men) were included, of whom 75 (51%) had high RVEDVI. This was associated with more frequent hospital admissions in the 12 months before admission (52/75 [69%] vs. 38/73 [52%], p = 0.04) and higher breathlessness (modified Medical Research Council score, 2.9 ± 1.3 vs. 2.4 ± 1.2, p = 0.007). During follow-up, high RVEDVI was associated with greater mortality (log-rank p = 0.001). In univariable Cox regression, increasing RVEDVI was associated with higher mortality (hazard ratio [HR]: 1.02 per ml/m2 ; 95% CI: 1.01, 1.03; p = 0.001). In multivariable Cox regression, RVEDVI was independently associated with mortality (HR: 1.01 per ml/m2 ; 95% CI: 1.00, 1.03; p = 0.050) at a borderline significance level. Adding RVEDVI to three COPD mortality prediction systems improved model fit (pooled chi-square test [BODE: p = 0.05, ADO: p = 0.04, DOSE: p = 0.02]). CONCLUSION: In patients with hospitalized AECOPD, higher RV end-diastolic volume was associated with worse acute clinical parameters and greater mortality.
引用
- Leong P, Osadnik CR, King PT, et al. Right ventricular end-diastolic volume and outcomes in exacerbations of COPD. Respirology. 2021. PMID: 34693587. doi:10.1111/resp.14170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。